Skip to main content

Table 2 Correlation of PB blast reduction ratio (PBRR) with treatment response

From: Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia

  PB blast reduction ratio (Log10) ( ± SD)
  Day 3 Day 5 Day 7 Day 9
CR (n = 67) 1.09 ± 0.62 2.49 ± 0.92 3.41 ± 1.02 3.92 ± 1.28
NCR (n = 29) 0.70 ± 0.53 1.70 ± 0.70 2.49 ± 0.95 2.91 ± 1.13
P value 0.005 <0.0001 <0.0001 <0.0001
MRD (+) n = 23) 1.05 ± 0.60 2.43 ± 1.05 3.19 ± 1.11 3.62 ± 1.41
MRD (−) (n = 29) 1.25 ± 0.64 2.69 ± 0.78 3.19 ± 1.11 4.15 ± 1.13
P value 0.266 0.334 0.162 0.157
Relapse (+) (n = 25) 0.85 ± 0.45 2.00 ± 0.68 2.83 ± 0.78 3.15 ± 1.02
Relapse (−) (n = 54) 1.12 ± 0.67 2.59 ± 0.93 3.57 ± 0.98 4.16 ± 1.19
P value 0.066 0.005 0.001 0.0005
Early relapsea (+) (n = 16) 0.80 ± 0.45 1.91 ± 0.80 2.76 ± 0.81 3.14 ± 1.10
Early relapsea (−) (n = 63) 1.10 ± 0.65 2.52 ± 0.89 3.48 ± 0.97 4.02 ± 1.19
P value 0.094 0.017 0.008 0.009
  1. CR achieved complete remission after one course of induction therapy, NCR not achieved complete remission, MRD minimal residual disease. aEarly relapse: hematologic relapse within 6 months.